MedTrace Logo

Allogeneic WTX-212C in Advanced Solid Tumors

NCT07556653 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-07-14

No results posted yet for this study

Summary

This is a multicenter, open-label, single-arm Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of allogeneic WTX-212C, an investigational allogeneic engineered red blood cell (RBC)-based product, in patients with advanced solid tumors who have failed standard therapies or have no available standard treatment options.

The study consists of a dose-escalation phase using a 3+3 design followed by a dose-expansion phase. Participants will receive allogeneic WTX-212C via intravenous infusion. Tumor assessments will be performed every 6 weeks according to RECIST 1.1.

Conditions

Interventions

DRUG

allogeneic WTX-212C

allogeneic WTX-212C is an investigational allogeneic engineered red blood cell-based injectable product administered intravenously.

Sponsors & Collaborators

  • Westlake Therapeutics

    collaborator INDUSTRY

  • First People's Hospital of Hangzhou

    collaborator OTHER

  • Zhejiang Provincial People's Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-26
Primary Completion
2027-04-09
Completion
2028-04-09

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07556653 on ClinicalTrials.gov